Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Department of Emergency Medical, Zhejiang Province People's Hospital, Zhejiang, China.
Clin Respir J. 2021 Oct;15(10):1027-1045. doi: 10.1111/crj.13407. Epub 2021 Jul 26.
Bronchial asthma is a heterogeneous disease with complex pathological mechanisms representing different phenotypes, including severe asthma. The airway epithelium is a major site of complex pathological changes in severe asthma due, in part, to activation of inflammatory and immune mechanisms in response to noxious agents. Current imaging procedures are unable to accurately measure epithelial and airway remodeling. Damage of airway epithelial cells occurs is linked to specific phenotypes and endotypes which provides an opportunity for the identification of biomarkers reflecting epithelial, and airway, remodeling. Identification of patients with more severe epithelial disruption using biomarkers may also provide personalised therapeutic opportunities and/or markers of successful therapeutic intervention. Here, we review the evidence for ongoing epithelial cell dysregulation in the pathogenesis of asthma, the sentinel role of the airway epithelium and how understanding these molecular mechanisms provides the basis for the identification of candidate biomarkers for asthma prediction, prevention, diagnosis, treatment and monitoring.
支气管哮喘是一种异质性疾病,其复杂的病理机制表现为不同的表型,包括严重哮喘。气道上皮细胞是严重哮喘复杂病理变化的主要部位,部分原因是对有害因子的炎症和免疫机制的激活。目前的成像程序无法准确测量上皮细胞和气道重塑。气道上皮细胞的损伤与特定的表型和内型有关,这为识别反映上皮细胞和气道重塑的生物标志物提供了机会。使用生物标志物识别上皮细胞破坏更严重的患者也可能提供个性化的治疗机会和/或成功治疗干预的标志物。在这里,我们回顾了哮喘发病机制中持续的上皮细胞失调的证据,气道上皮细胞的前哨作用,以及了解这些分子机制如何为识别哮喘预测、预防、诊断、治疗和监测的候选生物标志物提供基础。